Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentBeginning Cash BalanceBeginning Cash BalanceCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Picard Medical (PMI) Cash from Operations (2024 - 2026)

Picard Medical posted quarterly Cash from Operations of 3800000.0 for Q1 2026, down 69.57% year-on-year from 12486510.26 in Q1 2025, and up 13.18% on a QoQ basis from 4377000.0 in Q4 2025.

Picard Medical (PMI) has 3 years of Cash from Operations data on file, last reported at 3800000.0 in Q1 2026.

  • For the quarter ending Q1 2026, Cash from Operations fell 69.57% year-over-year to 3800000.0; the trailing twelve-month figure through Mar 2026 stood at 17232000.0 (changed N/A YoY), and the FY2025 full-year result was 15673000.0, down 31.99% from the prior year.
  • Cash from Operations for Q1 2026 stood at 3800000.0, up from 4377000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 2241000.0 in Q1 2025 and bottomed at 6514000.0 in Q3 2025.
  • The 3-year median for Cash from Operations is 3152000.0 (2024), against an average of 3604714.29.
  • Peak annual rise in Cash from Operations reached 38.86% in 2025, while the deepest fall reached 149.77% in 2025.
  • A 3-year view of Cash from Operations shows it stood at 3152000.0 in 2024, then slumped by 38.86% to 4377000.0 in 2025, then grew by 13.18% to 3800000.0 in 2026.
  • The last three Cash from Operations figures came in at 3800000.0 (Q1 2026), 4377000.0 (Q4 2025), and 6514000.0 (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Operations (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 1.32 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn 581.00 Mn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn 2.74 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn 348.00 Mn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn 43.80 Mn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn 220.10 Mn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn 525.60 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn 290.00 Mn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn 335.40 Mn
10 Picard Medical 12.10 Mn 12.10 Mn 275,000.00 -3.80 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -3.80 Mn
Mar 31, 2026 -3.80 Mn
Dec 31, 2025 -4.38 Mn
Dec 31, 2025 -4.38 Mn
Sep 30, 2025 -6.51 Mn
Sep 30, 2025 -6.51 Mn
Dec 31, 2024 -3.15 Mn
Dec 31, 2024 -3.15 Mn
Sep 30, 2024 -2.61 Mn
Sep 30, 2024 -2.61 Mn